Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 33 34 35

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Exum Instruments–TOFwerk: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument 2018-01-01
MedXCell–SEVERAL: investment, 2018 seed financing round CHF1.5m 2018-01-01
Pfizer–BioNTech: mRNA-based vaccines, 2018– collab development of influenza vaccines 2018-01-01
Roche–DiCE Molecules: small-molecule drug discovery, 201712– multi-year research collab €na using DiCE technology with Genentech 2017-12-19
Institut Virion\Sirion–ExpreS2ion Biotech: expression technology, 201712– collab using ExpreS2 platform for antigen production for IVD tests 2017-12-04
Anaveon–Basel (govt): investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch 2017-12-01
Anaveon–SEVERAL: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch 2017-12-01
Anaveon–Univ Zurich: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch 2017-12-01
SimLeap project–Bicoll: sweetener, 201711–2019 collab Bicoll is project partner 2017-11-17
SimLeap project–Charité: sweetener, 201711–2019 collab Charité is project partner 2017-11-17
SimLeap project–Germany (govt): grant, 201711–2019 BMB funding €1.1m out of total project volume of €1.6m 2017-11-17
SimLeap project–Symrise: sweetener, 201711–2019 collab Symrise is project partner 2017-11-17
Body Labs–Amazon: investment, 201710 acquisition €na (estimate $50m-$70m) of Body Labs by Amazon 2017-10-03
Labiotech.eu–SEVERAL: investment, 201709 2nd financing round €6-digit led by Wille AG + incl Simon Bungers 2017-09-18
Labiotech.eu–Wille Finance: investment, 201709 2nd financing round totalling €6-digit incl new + lead investor Wille AG 2017-09-18
GreenLight Biosciences–SEVERAL: investment, 201709 financing round Series D $18m led by Fall Line Capital 2017-09-13
Repare Therapeutics–SEVERAL: investment, 201706 financing round Series A $68m co-led by Versant Ventures + MPM Capital 2017-06-22
Hopp Group–CRS Clinical Research Services: investment, 201706 management buy-out of CRS from LTS via holding Apleonex AG 2017-06-19
Kaken Pharmaceutical–Numab: therapeutic antibody, 201706– collab + license option €na for multispecific antibody for inflammatory disease 2017-06-13
Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution 2017-06-01
Cardior Pharmaceuticals–BioMedPartners: investment, 201705 financing round Series A totalling €15m incl co-lead investor BioMedInvest III Fund 2017-05-11
Cardior Pharmaceuticals–BMS: investment, 201705 financing round Series A totalling €15m incl co-lead investor BMS 2017-05-11
Cardior Pharmaceuticals–Boehringer: investment, 201705 financing round Series A totalling €15m incl co-lead investor BIVF 2017-05-11
Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 201705 financing round Series A totalling €15m incl co-lead investor HTGF 2017-05-11
Cardior Pharmaceuticals–Life Sciences Partners: investment, 201705 financing round Series A totalling €15m incl co-lead investor LSP 2017-05-11
Elitech–PAI Partners: investment, 201705– acquisition of Elitech Group by PAI Partners from Ergon Capital Partners 2017-05-11
Caladrius–Hitachi: investment, 201705 acquisition of PCT LLC by Hitachi Chemical 2017-05-01
TolerogenixX–Germany (govt): grant, 201705 BMWi Exist Forschungstransfer grant €1.4m 2017-05-01
Sinopharm–Oncgnostics: molecular diagnostics, 201704– license excl for Gyntect test to CJMT/GeneoDx for China + Hong Kong + Macao 2017-04-05
Axolabs–LGC: investment, 201703 acquisition of Axolabs GmbH by LGC 2017-03-01
Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck 2017-01-12
ArchiMed–SEVERAL: investment, 2017 closing of MED II Fund at €315m 2017-01-01
Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund 2017-01-01
Inveox–SEVERAL: investment, 2017 seed financing round €1m from four business angels 2017-01-01
Mestex–SEVERAL: investment, 2017 2nd financing round 2017-01-01
Swixx Biopharma–HBM: investment, 2017 initial investment of HBM Healthcare Investments in Swixx Biopharma AG 2017-01-01
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares 2016-12-19
Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II 2016-12-01
T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors 2016-11-23
Celonis–SEVERAL: investment, 201606 financing round Series A $27.5m 2016-06-01
Labiotech.eu–WestTech Ventures: investment, 201602 seed financing round totalling low €6-digit incl lead investor WestTech Ventures 2016-02-03
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock 2015-07-14
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital 2015-03-04
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne 2015-03-04
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund 2015-03-04
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures 2015-03-04
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One 2015-03-04
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit 2015-03-03
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € 2015-01-01
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF 2015-01-01
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) 2015-01-01
Tricares–CapDecisif: investment, 2015 seed financing round incl investor CapDecisif Management 2015-01-01
Tricares–Crédit Mutuel-CIC: investment, 2015 seed financing round incl investor CM-CIC Innovation 2015-01-01
Tricares–GO Capital: investment, 2015 seed financing round incl investor GO Capital 2015-01-01
Tricares–SEVERAL: investment, 2015 seed financing round with CapDecisif + GO Capital + CM-CIC Innovation 2015-01-01
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg 2014-08-01
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
ArchiMed–SEVERAL: investment, 2014 closing of MED I Fund at €150m 2014-01-01
Electrochaea–SEVERAL: investment, 2014 financing round Series A 2014-01-01
Mestex–SEVERAL: investment, 2014 1st financing round 2014-01-01
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m 2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR 2014-01-01
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors 2013-12-19
Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund 2013-11-18
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery 2013-01-01
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch 2012-12-04
Vivacta–Novartis: investment, 2012 acquisition by Novartis 2012-01-01
AVISO GmbH–ALS Automated Lab Solutions: investment, 2011 newly found ALS acquires all assets of AVISO keeping core team intact 2011-01-01
Boehringer–Minapharm: rec protein production technology, 2011– collab Boehringer early adopter of ProBioGen’s GlymaxX afucosylation technology 2011-01-01
Meiji Seika Kaisha–Newron: safinamide, 2011– license to develop + manufacture + commercialise safinamide in Asia to Meiji Seika Pharma 2011-01-01
Rebiotix–SEVERAL: investment, 2011 seed financing round $5m 2011-01-01
FoldRx–Pfizer: investment, 202009– acquisition $53m by Pfizer 2010-09-01
China National Nuclear–ITM: radiopharmaceuticals, 2010– collab strategic partnership with CIRC in China 2010-01-01
KLIFO–PERSON: investment, 2008 acquisition of KLIFO A/S by Alejandra Mørk who joins as CEO 2008-01-01
Traceless Materials–b.value: investment, 202104 seed financing round totalling lower €7-digit incl investor b.value AG 2000-04-01
Traceless Materials–High-Tech Gründerfonds: investment, 202104 seed financing round totalling lower €7-digit incl investor HTGF 2000-04-01
Traceless Materials–Planet A: investment, 202104 seed financing round totalling lower €7-digit incl investor Planet A 2000-04-01
Traceless Materials–SEVERAL: investment, 202104 seed financing round lower €7-digit from Planet A + HTGF + b.value 2000-04-01
Hoechst–Clariant: investment, 1997 acquisition of Hoechst Speciality Chemical Business by Clariant 1997-01-01
Evonik–Univ Mainz: lipid vectors, 202402– license for rPEG lipids for nucleic acid delivery from Univ Mainz
Mind NRG–Minerva Neurosciences: investment, before 202008 acquisition of Mind NRG (CH) by Minerva Neurosciences
OTHER–Novartis: investment, 201401 acquisition of biologics manufacturing faciltiy in Longmont CO by AveXis
next pagenext page 1 2 3 ... 33 34 35



Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x300px

» top